Attendance at Thalassemia International Federation (TIF) Conference in Greece TIF’s International Conference constitutes the biggest educational event in the field of hemoglobin disorders organized on a global scale and comprised of two parallel Conferences, namely
Hemanext Sponsors Rome Workshop Hosted by Centro Nazionale Sangue Hemanext recently sponsored a workshop hosted by the Centro Nazionale Sangue (CNS, or commonly known as the Italian National Blood Centre), a division of the Ministry
Whirlwind Tour of International Congresses The last couple of months have been extremely exiting for Hemanext in the international transfusion medicine industry. Following the 2017 AABB meeting in San Diego, Hemanext was off to the
Hemanext had a major presence at the 2017 AABB Annual Meeting where we showcased our Hemanext RBC Processing System and Microvascular Analyzer (MVA) technology, our proprietary solution for assessing deformability of stored red blood cells.
We are proud to announce the acceptance and presentation of “Oxygen Content – Uncontrolled and Overlooked Parameter Associated with Stored Red Cell Concentrate: Unexpectedly Wide Distribution” abstract and poster at the recent International Society of
Annual Shareholder Meeting to be held May 5, 2017. Details posted in Investor Portal in 04-18-2017 Shareholder Letter.
Wide Distribution of Initial Oxygen Saturation Levels in Red Cells Stored for Transfusion, May Significantly Influence Cell Quality and Therapeutic Efficacy
Bethesda, MD – March 6, 2017 – New Health Sciences, Inc. (NHSi), a medical technology company focused on improving transfusion therapy, is happy to announce the completion and recent publication of their study exploring the
New Health Sciences has closed an additional $6.0 million Series B financing raised from existing private investors. NHSi will use the new capital to fund continued development of its Hemanext technology and to support an